Comparative Pharmacology
Head-to-head clinical analysis: ILOSONE SULFA versus THIOSULFIL.
Peer-Reviewed Evidence
Head-to-head clinical analysis: ILOSONE SULFA versus THIOSULFIL.
ILOSONE SULFA vs THIOSULFIL
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ilosone (erythromycin) is a macrolide antibiotic that inhibits bacterial protein synthesis by binding to the 50S ribosomal subunit. Sulfa (sulfisoxazole) is a sulfonamide that inhibits dihydropteroate synthase, blocking folate synthesis. The combination provides synergistic bacteriostatic activity.
Thiosulfil (sulfamethizole) is a sulfonamide antibiotic that inhibits bacterial dihydropteroate synthase, blocking folic acid synthesis and thereby nucleic acid production.
Each 5 mL suspension contains 250 mg erythromycin base and 600 mg sulfisoxazole; typical adult dose is 10 mL (2 tsp) every 6 hours, not to exceed 40 mL/day.
500 mg orally twice daily for 10-14 days.
None Documented
None Documented
Erythromycin: 1.5-2 hours; Sulfisoxazole: 4-7 hours; clinical context: dose adjustment in renal impairment (CrCl <50 mL/min) needed for sulfisoxazole
Terminal elimination half-life is 2-4 hours in patients with normal renal function (creatinine clearance >80 mL/min); prolonged to 20-50 hours in severe renal impairment (CrCl <30 mL/min).
Renal: 70-80% as unchanged drug and active metabolite (sulfisoxazole); Biliary: 10-15% as metabolites; Fecal: <5%
Renal: 70-90% as unchanged drug via glomerular filtration and tubular secretion. Biliary/fecal: <5%.
Category C
Category C
Macrolide and Sulfonamide Antibiotic
Sulfonamide Antibiotic